UnknownPhase 2NCT03570437
Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?
Studying Carcinosarcoma of the corpus uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Manchester
- Principal Investigator
- Gordon JaysonThe Christie NHS Foundation Trust
- Intervention
- Paclitaxel(drug)
- Enrollment
- 124 enrolled
- Eligibility
- 16 years · FEMALE
- Timeline
- 2018 – 2023
Study locations (15)
- Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom
- Royal Surrey County Hospital, Guildford, Surrey, United Kingdom
- Royal United Hospitals Bath NHS Foundation Trust, Bath, United Kingdom
- Bristol Haematology & Oncology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
- Velindre Cancer Centre, Velindre University NHS Trust, Cardiff, United Kingdom
- Beatson West of Scotland Oncology Centre, Glasgow, United Kingdom
- Airedale NHS Foundation Trust, Keighley, United Kingdom
- Hope Clinical Trials Facility, Leicester Royal Infirmary, Leicester, United Kingdom
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom
- University College London Hospitals NHS Foundation Trust, London, United Kingdom
- Guys & St Thomas NHS Trust, London, United Kingdom
- Royal Marsden Hospitals, London, United Kingdom
- The Christie NHS Foundation Trust, Manchester, United Kingdom
- Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, United Kingdom
- The Churchill Hospital, Old Road, Headington, Oxford, United Kingdom
Collaborators
AstraZeneca · Cardiff University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03570437 on ClinicalTrials.govOther trials for Carcinosarcoma of the corpus uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07029399A Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsNiKang Therapeutics, Inc.
- RECRUITINGPHASE2NCT05619913EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine CarcinosarcomaAustralia New Zealand Gynaecological Oncology Group
- ACTIVE NOT RECRUITINGPHASE2NCT05147558A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine CarcinosarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1, PHASE2NCT03686124ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsImmatics US, Inc.